INTRODUCTION

Epithelial ovarian cancer (EOC) is the second most common gynecologic malignancy in developed countries, and accounts for more deaths than the remaining gynecologic cancers added together [1]. EOC can spread by intraperitoneal seeding, direct invasion, or through lymphatic or vascular circulation, and the peritoneal seeding is the most common route of dissemination [2]. In most women with EOC, the disease is not diagnosed until it is at an advanced stage. Primary cytoreductive surgery followed by taxane/platinum-based adjuvant chemotherapy is considered the standard approach to these patients [3]. Some observers have noted that the maximal cytoreduction, correlated to the minimal residual tumor mass after surgery, is one of the most powerful prognostic factors [4-6].

Objective: To determine whether \(^{18}\)F FDG uptake on PET/CT imaging before surgical staging has prognostic significance in patients with epithelial ovarian cancer (EOC).

Methods: Patients with EOC were imaged with integrated PET/CT before surgical staging. Hypermetabolic lesions were measured as the standardized uptake value (SUV) in primary and metastatic tumors. SUV distribution was divided into two regions at the level of umbilicus, and the impact of the ratio between above and below umbilicus (SUV\(_{\text{location}}\) ratio) on progression-free survival (PFS) was examined using Cox proportional hazards regression.

Results: Between January 2004 and December 2009, 55 patients with EOC underwent preoperative PET/CT. The median duration of PFS was 11 months (range, 3 to 43 months), and twenty (36.4%) patients experienced recurrence. In univariate analysis, high SUV\(_{\text{location}}\) ratio (p=0.002; hazard ratio [HR], 1.974; 95% confidence interval [CI], 1.286 to 3.031) was significantly associated with recurrence. Malignant mixed Mullerian tumor compared with endometrioid histology was also shown to have significance. In multivariate analysis, high SUV\(_{\text{location}}\) ratio (p=0.005; HR, 2.418; 95% CI, 1.1315 to 4.447) and histology (serous, mucinous, and malignant mixed Mullerian tumor compared with endometrioid type) were significantly associated with recurrence. Patients were categorized into two groups according to SUV\(_{\text{location}}\) ratio (<0.3934 vs. ≥0.3934), and the Kaplan-Meier survival graph showed a significant difference in PFS between the groups (p=0.0021; HR, 9.47, log-rank test).

Conclusion: SUV distribution showed a significant association with recurrence in patients with EOC, and may be a useful predictor of recurrence.

Keywords: Distribution, Epithelial ovarian cancer, Recurrence, Standardized uptake value
by means of contrast-enhanced CT, however, the sensitivity of this technique depends on the size and location of peritoneal implants. Moreover, anatomical imaging uses only size criteria and does not recognize the functional alterations that occur within tumor tissue. PET/CT using $[^{18}F]FDG$ has been successfully employed to visualize enhanced glucose utilization in tumor tissues. PET/CT has been shown to identify primary tumors, regional lymph nodes, and distant metastases with high diagnostic accuracy for primary and recurrent EOC [7-10]. These hybrid systems perform both PET and CT and co-register images with an improvement of anatomic localization of intra- and extra-pelvic structures [11], as well as allowing the detection of distant supra-diaphragmatic metastases [12]. Several studies have shown that PET or PET/CT were useful for monitoring treatment response [13,14], detecting residual disease after completion of therapy [15,16], and detecting recurrent or metastatic lesions in EOC [8,17].

However, only limited information is currently available describing the role of PET/CT for the prediction of recurrence in EOC. This study evaluated the hypothesis that the pretreatment metabolic activities measured by FDG uptake and its distribution will allow prediction of prognosis. The aim of this study was to evaluate the prognostic value of the distribution of FDG uptake on preoperative PET/CT scans in patients with EOC.

**MATERIALS AND METHODS**

1. **Patient population**

This study was approved by our institutional review board. We retrospectively reviewed the tumor registry at our institution and identified all patients diagnosed with EOC between January 2004 and December 2009. All clinical, histological and imaging data of patients at our institution were collected and stored in a computerized database. Patients were required to have undergone an PET/CT study just before establishing a pathologic diagnosis, to have received no treatment before the study, and to have had at least 3 months of follow-up.

Patients were excluded in the analysis if any of the following criteria were present: 1) a previous diagnosis of another malignant disease or borderline tumor, 2) short follow-up duration less than 3 months, 3) primary treatment other than surgery such as neoadjuvant chemotherapy, 4) known allergy to contrast media, diabetes or other severe medical conditions. Tumor histologic cell type, grade, stage at surgical staging, site of metastasis, and treatment were recorded from the patient’s medical record. A stage after surgical staging was assigned according to the International Federation of Gynecology and Obstetrics (FIGO).

2. **PET/CT imaging**

The patients were imaged using a dedicated PET/CT system (Gemini, Philips Medical Systems, Andover, MA, USA). All patients were instructed to fast at least 4 hours prior to undergoing PET/CT; 125 mL of a barium sulfate solution (Readicat [1.3% weight-volume barium sulfate suspension]; E-Z-EM, Westbury, NY, USA or EZCT [1.5% weight-volume barium sulfate suspension], Taejoon Pharm, Seoul, Korea) was administered orally 1 hour prior to imaging to opacify the bowel for the CT portion of the study, following methods described in our previous study [18]. PET/CT scans were obtained between 1 day and 23 days (median, 5 days) before surgery.

3. **Image analysis**

All images were interpreted and analyzed by two experienced nuclear medicine physicians (HWK, KWK) with all available clinical information. The images were reviewed on an interactive video display provided by the equipment manufacturer standardized uptake value (SUV) was quantitatively used to determine FDG activity. Calculation of SUV was as follows: SUV = $C_{max} \times TBW/IA$ ($C_{max}$, activity concentration in the voxel of highest metabolic activity [Bq/mL]; $TBW$, total body weight [kg]; $IA$, injected activity [kBq]).

SUV distribution was divided into two regions at the level of the umbilicus, and the impact of the ratio between above and below the umbilicus (SUV$_{ratio}$ = sum of SUV above umbilicus / sum of SUV below umbilicus) on recurrence was examined.

4. **Treatment and follow-up**

After the PET/CT scan and a definitive surgical staging, 50 patients were treated with chemotherapy. Survival data were obtained from the tumor registry and verified on review of the medical records.

5. **Histological and clinical evaluation**

Recurrent disease was confirmed in all cases by either tissue biopsy or the demonstration of progressive disease by serial imaging studies such as CT, MRI, or PET/CT. Clinical proof of no recurrent disease consisted of a negative tissue biopsy and negative findings on serial follow-up imaging studies.

To confirm lesions detected on PET/CT imaging, CT- or ultrasound-guided biopsy was performed to obtain tissues for histological evaluation in cases where it was considered necessary for patient management. Progressive elevation of serum tumor marker (CA-125) accompanied by an increase in lesion size or the appearance of new lesions was considered disease recurrence.
6. Data analysis

With respect to SUV location ratio, receiver operating characteristic (ROC) curve analysis was performed in order to determine the cutoff values for predicting recurrence. Progression-free survival (PFS) was calculated as the interval from the date of treatment completion to the first documented date of progression, or death whichever occurred first. Survival curves were constructed using the method of Kaplan and Meier. The Cox proportional hazards modeling used to identify independent variables associated with recurrence. Results from the Cox models are expressed as hazard ratios (HRs) with 95% confidence intervals (CIs), and p<0.05 was considered the level of significance. The SPSS ver. 11.0 (SPSS Inc., Chicago, IL, USA) was used for the statistical analysis.

RESULTS

1. Characteristics of the patients

Of the 337 patients diagnosed as EOC, 299 patients underwent primary debulking surgery during the study period. There were 76 patients with a median age of 54 years (range, 35 to 80 years) who met the inclusion criteria. A total of 55 patients underwent preoperative PET/CT scanning.

2. PET/CT and survival

Median follow-up time was 16 months (range, 3 to 50 months), and the median PFS duration was 11 months (range, 3 to 43 months). Twenty (36.4%) patients experienced recurrence, and one patient died of disease. The 3-year PFS rate was 50.8%.

3. Cutoff value of SUV location ratio

Fig. 1 shows the ROC curve analyzing the SUV location ratio in PFS. Area under the curve (AUC) was 0.740 (p=0.004; 95% CI, 0.607 to 0.873), and the value of 0.3934 was determined as the cutoff of SUV location ratio in this study, and patients were categorized into two groups according to the SUV location ratio (<0.3934 vs. ≥0.3934). Table 1 lists the descriptive statistics among demographic subgroups categorized by the cutoff SUV location ratio. Patient distribution was significantly different according to FIGO stage (p=0.015), residual disease after surgery (p=0.017), and patients status (p=0.004) between the two groups categorized by the SUV location ratio. Table 2 lists the median PFS among groups categorized by the cutoff SUV location ratio.

4. SUV location ratio and recurrence

Table 3 shows the results of the Cox proportional hazard analyses. In univariate analysis, high SUV location ratio (p=0.002; HR, 1.974; 95% CI, 1.286 to 3.031) was significantly associated with recurrence. Malignant mixed mullerian tumors (MMMT) compared with endometrioid histology was also shown to have significance. In multivariate analysis, high SUV distribution ratio (p=0.005; HR, 2.418; 95% CI, 1.1315 to 4.447), and histology (serous, p=0.031; mucinous, p=0.045; MMMT, p=0.003; compared with endometrioid type) were significantly associated with recurrence. The Kaplan-Meier survival graph showed a significant difference in PFS between the groups categorized by SUV location ratio (Fig. 2). Survival difference between the two groups was statistically significant (p=0.0021, log-rank test).

DISCUSSION

The purpose of the current study was to determine whether the preoperative metabolic tumor burden and its distribution as measured by the SUV have prognostic significance in patients with EOC. To the best of our knowledge, this is the first study reporting the prognostic value of preoperative PET/CT on predicting the risk of recurrence in patients with EOC.

The principle finding was that the metabolic tumor burden in the upper abdomen measured as SUV location ratio on preoperative PET/CT was the most powerful significant prognostic factor for predicting recurrence in EOC. It is noteworthy that FIGO stage was not a significant prognostic factor for recurrence in this study. This may be due to the small number of patients enrolled, and the distribution of stage (most patients were stage III). We found that another tumor-related factor such as tumor histology was also a predictor of recurrence.
The results of the current study demonstrate the potential value of preoperative PET/CT in patients with preoperative SUV\textsubscript{location} ratio. We aim to perform more frequent and intensive follow-up or prophylactic administration of consolidation treatment in these patients, and may individualize patient care according to the preoperative SUV\textsubscript{location} ratio.

In previous studies, the presence of residual tumor after primary surgery has been shown to be an independent prognostic factor [19-23]. A Gynecologic Oncology Group (GOG) study demonstrated that patients with stage III disease presenting with large-volume ovarian cancer before undergoing optimal cytoreduction had a worse prognosis than patients found to have small-volume disease at the time of exploration [24].

The Scottish Randomized Trial in Ovarian Cancer (SCOTROC) showed that a clinically significant PFS benefit with optimal surgery among patients with stage IC to IV disease was limited to patients with less advanced disease [25].

Adding values of lesional SUVs may imply the importance of tumor burden, and it may depend on the number of metastatic lesions without information of tumor volume. In this respect, we calculated the metabolic tumor volume (MTV) and performed analysis using the sum of MTVs. However, preoperative MTV was not an independent prognostic factor of recurrence in the current study (data not shown). Here, we hypothesized that the locus of the metastatic tumor burden would have prognostic importance.

### Table 1. Patient characteristics for epithelial ovarian cancer: comparison of groups categorized by the ratio of the location of hypermetabolism

| Variable                  | SUV\textsubscript{location} ratio < 0.3934 | SUV\textsubscript{location} ratio ≥ 0.3934 | p-value* | SUV\textsubscript{location} ratio |
|---------------------------|------------------------------------------|------------------------------------------|----------|----------------------------------|
| Age (yr)                  | 54 (35-80)                              | 53 (36-80)                              | 0.431    | 54 (35-80)                      |
| FIGO stage                |                                         |                                          | 0.015    |                                  |
| I                         | 5 (18.5)                                | 1 (3.6)                                 |          | 0 (0-0.69)                      |
| II                        | 5 (18.5)                                | 0 (0.0)                                 |          | 0 (0-0.12)                      |
| III                       | 17 (63.0)                               | 26 (92.9)                               | 0.55     | 0 (3-3.9)                       |
| IV                        | 0 (0.0)                                 | 1 (3.6)                                 | 0.98     |                                  |
| Histology                 |                                         |                                          | 0.07     |                                  |
| Serous                    | 12 (44.4)                               | 22 (78.6)                               | 0.63     | 0 (3-3.1)                       |
| Mucinous                  | 2 (7.4)                                 | 0 (0.0)                                 | 0        |                                  |
| Endometrioid              | 7 (25.9)                                | 3 (10.7)                                | 0        | 0 (3-3.1)                       |
| Clear cell                | 1 (3.7)                                 | 0 (0.0)                                 | 0        |                                  |
| Undifferentiated          | 2 (7.4)                                 | 1 (3.6)                                 | 0.35     | 0.31-0.97                       |
| MMMT                      | 1 (3.7)                                 | 2 (7.1)                                 | 0.57     | 0 (3-3.9)                       |
| Transitional cell         | 2 (7.4)                                 |                                         |          |                                  |
| CA-12S                    | 650 (8-4,620)                           | 810 (3-43,530)                          | 0.399    | 750 (3-43,530)                  |
| Grade                     |                                         |                                          | 0.255    |                                  |
| 1                         | 4 (14.8)                                | 1 (3.6)                                 | 0        | 0 (0-0.69)                      |
| 2                         | 6 (22.2)                                | 3 (10.7)                                | 0        | 0 (0-0.66)                      |
| 3                         | 16 (59.3)                               | 22 (78.6)                               | 0.56     | 0 (3-3.9)                       |
| Unknown                   | 1 (3.7)                                 | 2 (7.1)                                 | 0.60     | 0.13-1.23                       |
| Residual after surgery    |                                         |                                          | 0.017    |                                  |
| Yes                       | 6 (22.2)                                | 15 (53.6)                               | 0.94     | 0 (3-3.9)                       |
| No                        | 21 (77.8)                               | 13 (46.4)                               | 0.18     | 0 (3-3.1)                       |
| Patient status            |                                         |                                          | 0.004    |                                  |
| NED                       | 23 (85.2)                               | 12 (42.9)                               | 0.21     | 0 (3-3.1)                       |
| AWD                       | 4 (14.8)                                | 15 (53.6)                               | 0.66     | 0 (3-3.9)                       |
| EXP                       | 0 (0.0)                                 | 1 (3.6)                                 | 1.0      |                                  |

Values are presented as mean (range) or number (%). All p-values result from a \( \chi^2 \) test except for the variable of age and CA-12S, in which a t-test was performed.

SUV\textsubscript{max}, maximum standardized uptake value; FIGO, International Federation of Obstetrics and Gynecology; MMMT, malignant mixed müllerian tumor; NED, no evidence of disease; AWD, alive with disease; EXP, expired.
Table 2. Median progression-free survival among groups categorized by the ratio of the location of hypermetabolism

| Variable                  | SUV<sub>location ratio</sub> < 0.3934 | SUV<sub>location ratio</sub> ≥ 0.3934 | Overall |
|---------------------------|---------------------------------------|--------------------------------------|---------|
|                           | No. | No. recur | Median PFS (mo) | No. | No. recur | Median PFS (mo) | No. | No. recur | Median PFS (mo) |
| FIGO stage                |     |           |                 |     |           |                 |     |           |                 |
| I                         | 5    | 0         | 16.2            | 1    | 0         | 30.4            | 6    | 0         | 18.0            |
| II                        | 5    | 0         | 10.4            | 0    | 0         | 0               | 5    | 0         | 10.4            |
| III                       | 17   | 4         | 10.5            | 26   | 15        | 9.8             | 43   | 19        | 10.2            |
| IV                        | 0    | 0         | 1               | 1    | 1         | 11.1            | 1    | 1         | 11.1            |
| Histology                 |     |           |                 |     |           |                 |     |           |                 |
| Serous                    | 12   | 3         | 10.3            | 22   | 13        | 10.7            | 34   | 16        | 10.5            |
| Mucinous                  | 2    | 1         | 9.9             | 0    | 0         | 0               | 2    | 1         | 9.9             |
| Endometrioid              | 7    | 0         | 16.2            | 3    | 1         | 15.2            | 10   | 1         | 10.5            |
| Clear cell                | 1    | 0         | 19.8            | 0    | 0         | 0               | 1    | 0         | 19.8            |
| Undifferentiated          | 2    | 0         | 22.6            | 1    | 0         | 4.0             | 3    | 0         | 9.5             |
| MMMT                      | 1    | 0         | 3.3             | 2    | 2         | 6.0             | 3    | 2         | 3.3             |
| Transitional cell         | 2    | 0         | 29.0            | 0    | 0         | 0               | 2    | 0         | 29.0            |
| Grade                     |     |           |                 |     |           |                 |     |           |                 |
| 1                         | 4    | 1         | 15.4            | 1    | 0         | 30.4            | 5    | 1         | 16.2            |
| 2                         | 6    | 0         | 14.8            | 3    | 2         | 11.1            | 9    | 2         | 13.6            |
| 3                         | 16   | 3         | 11.8            | 22   | 13        | 9.8             | 38   | 16        | 10.3            |
| Unknown                   | 1    | 0         | 10.5            | 2    | 1         | 17.4            | 3    | 1         | 10.5            |
| Residual after surgery    |     |           |                 |     |           |                 |     |           |                 |
| Yes                       | 6    | 2         | 8.7             | 15   | 8         | 10.8            | 21   | 10        | 9.8             |
| No                        | 21   | 2         | 14.5            | 13   | 8         | 9.8             | 34   | 10        | 12.4            |

SUV<sub>max</sub>, maximum standardized uptake value; PFS, progression-free survival; FIGO, International Federation of Obstetrics and Gynecology; MMMT, malignant mixed müllerian tumor.

Table 3. Results of analyses of prognostic factors for progression-free survival

| Variable                  | Test for favorable status | Hazard ratio | 95% confidence interval | p-value |
|---------------------------|---------------------------|--------------|-------------------------|---------|
| Univariate analysis       |                           |              |                         |         |
| Age                       | 1.012                     | 0.973-1.054  | 0.549                   |         |
| FIGO stage                | Stage III-IV vs. stage I-II | 33.774      | 0.450-2535.840         | 0.110   |
| Histology                 | Serous vs. endometrioid   | 7.565        | 0.990-57.821           | 0.051   |
|                           | MMMT vs. endometrioid     | 46.067       | 3.793-555.432          | 0.003   |
| SUV<sub>max</sub> (uncategorized) | 0.997                 | 0.979-1.016  | 0.764                   |         |
| Serum CA-12S              | ≥298.5 vs. <298.5         | 2.423        | 0.702-8.361            | 0.161   |
| Residual tumor            | Yes vs. no               | 1.853        | 0.749-4.584            | 0.182   |
| SUV<sub>location</sub> ratio (uncategorized) | 1.974 | 1.286-3.031 | 0.002 |         |
| Metabolic tumor volume    | ≥46.24 vs. <46.24         | 2.421        | 0.917-6.391            | 0.074   |
| Multivariate analysis     |                           |              |                         |         |
| SUV<sub>location</sub> ratio (uncategorized) | 2.418 | 1.315-4.447 | 0.005 |         |
| Histology                 | Serous vs. endometrioid   | 10.639       | 1.237-91.494           | 0.031   |
|                           | MMMT vs. endometrioid     | 63.514       | 4.293-939.632          | 0.003   |
|                           | MMMT vs. mucinous         | 22.442       | 1.075-468.523          | 0.045   |

FIGO, International Federation of Obstetrics and Gynecology; SUV<sub>max</sub>, maximum standardized uptake value; MMMT, malignant mixed müllerian tumor.
One of the main pitfalls of PET imaging is the non-invasive visualization of diffuse peritoneal carcinomatosis, with the tumor spread through small implants on the peritoneal surface: the problem emanates from the reduced spatial resolution of PET imaging (5-6 mm) that makes it unable to visualize minute tumor implants, as in miliary carcinomatosis.

We recognize several limitations of this study. Most notably is that it was a retrospective study performed at a single institution with a relatively small number of patients (n=55). There may have been selection bias. Not all patients with EOC underwent preoperative PET/CT during the study period. The physician's attitude to PET/CT may have influenced the referral of patients in the retrospective study design. Hence, our findings may not be generalizable to all EOC patients, as only selected patients may have been referred to PET/CT scanning, and image acquisition and interpretation procedures will be different according to institutions. Additional standardized large prospective studies may be necessary to confirm the prognostic value of preoperative PET/CT in clinical practice. Additional standardized large prospective studies may be necessary to confirm the prognostic value of preoperative PET/CT in clinical practice. Second, we could not analyze the overall survival because there was only one case of disease-related death among the study population, and the study period was relatively short since PET/CT has only recently been introduced at our institution. We are preparing a prospective study to confirm the currently reported results, and eventually to determine if pre-treatment PET/CT has predictive prognosis value.

Although this study has some limitations, it also demonstrates unique and significant findings, because to the best of our knowledge no study published to date has demonstrated the prognostic significance of metabolic burden in patients with EOC. The findings of the current study have important implications for the management of patients with EOC; patients with high SUV_{location} ratio in preoperative PET/CT scan should be closely monitored after treatment, or consolidation treatment after previously-planned therapy may be seriously considered. In addition, targeting molecular therapeutics using tumor metabolism might be proposed and be a candidate theme of future research in the treatment of EOC.

In conclusion, preoperative SUV_{location} ratio was a significant prognostic indicator for recurrence in patients with EOC, and may allow individualization of patient care. Further analysis with a larger patient population and longer follow-up is warranted for confirmation of the findings of this study.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary: FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S161-92.
3. Park TW, Kuhn WC. Neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther 2004;4:639-47.
4. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
5. Naik R, Nordin A, Cross PA, Hemming D, de Barros Lopes A, Monaghan JM. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. Gynecol Oncol 2000;78:171-5.
6. Heintz AP, Hacker NF, Berek JS, Rose TP, Munoz AK, Lagasse LD. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 1986;67:783-8.
7. Prakash P, Cronin CG, Blake MA. Role of PET/CT in ovarian cancer. AJR Am J Roentgenol 2010;194:W464-70.
8. Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 2007;
Kitajima K, Murakami K, Yamasaki E, Kaji Y, Fukasawa I, Inaba N, et al. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging 2008;35:1912-20.

Dirisamer A, Schima W, Heinisch M, Weber M, Lehner HP, Haller J, et al. Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT. Eur J Radiol 2009;69:536-41.

Townsend DW, Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol 2002;75(Spec No):S24-30.

Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P, et al. Distant metastases in ovarian carcinoma. Int J Gynecol Cancer 2003;13:125-9.

Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445-53.

Nishiyama Y, Yamamoto Y, Kanenishi K, Ohno M, Hata T, Kushida Y, et al. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET. Eur J Nucl Med Mol Imaging 2008;35:287-95.

Sironi S, Messa C, Mangili G, Zangheri B, Aletti G, Garavaglia E, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histological findings. Radiology 2004;233:433-40.

Kim S, Chung JK, Kang SB, Kim MH, Jeong JM, Lee DS, et al. [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian cancer. Eur J Nucl Med Mol Imaging 2004;31:196-201.

Soussan M, Wartski M, Cherel P, Fourme E, Goupil A, Le Stanc E, et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol 2008;108:160-5.

Chung HH, Kang WJ, Kim JW, Park NH, SongYS, Chung JK, et al. The clinical impact of [18F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings. Eur J Nucl Med Mol Imaging 2008;35:1081-8.

Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.

Eisenkop SM, Spirtos NM, Lin WC. “Optimal” cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol 2006;103:329-35.

Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage III/IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103:559-64.

Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A, et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival: an exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007;106:69-74.

Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol 2007;105:84-9.

Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-66.

Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 2005;23:8802-11.